Collection of Blood and Tissue Samples From Patients and Family Members With Known or Suspected Urologic Cancers and Genetic Risks

What this Trial Is About

Researchers are studying the genetic causes and molecular characteristics of urologic cancers including kidney, prostate, bladder, testis, and penile cancers. These cancers make up a significant portion of cancer diagnoses and deaths in the United States. The goal is to better understand gene pathways involved in these malignancies to aid in developing targeted treatments. This observational study collects blood, urine, and tissue samples from individuals with confirmed or suspected malignant disease or inherited urologic cancer risks. Participants include patients with biopsy-proven or suspected malignancies and their blood relatives who may have inherited cancer risks. Samples of blood, urine, and both normal and malignant tissue are collected during clinical visits and surgeries. These specimens are stored in a tissue bank and used for genetic sequencing, protein expression analysis, and research on cancer gene mutations and biochemical pathways. The study also investigates quality of life in men with prostate cancer and responses to existing and novel cancer therapies. During the study, participants undergo eligibility screening and may provide biological samples at initial and periodic visits. Tissue samples are collected during clinically indicated surgeries. Researchers analyze these samples using molecular and biochemical methods to identify genetic differences and markers. Participants may be contacted if significant health-related findings arise. The study involves ongoing assessments of genetic and molecular data and quality of life, continuing over time without a fixed end date.

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease